Clinical trials: Vector-Borne Diseases
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
The aim of the study was to assess the immune response and the safety of different vaccination schedules of CYD dengue vaccine. The primary objectives of the study were: To demonstrate the non-inferiority of the immune response…
- Trial name
- NCT02628444
- Testing
- CYD Dengue Vaccine
- Where
- 6 sites in Colombia, Philippines
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Malaria
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.
Phase 1, single -centre study in 2 parts. The study designs for each part are well established for first-in-human studies and are appropriate to assess safety, tolerability and preliminary pharmacokinetics.
- Trial name
- NCT04323306
- Testing
- MMV688533
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Covid19, Paludism
Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID)
In this study, the investigators will explore the reasons for the apparently lower proportion of severe COVID-19 cases in many sub-Sahara African countries.
- Trial name
- Palu-COVID (NCT05012280)
- Where
- Democratic Republic of the Congo
- Volunteers
- 238 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
This study is designed to characterise P. falciparum transmission intensity in subjects aged ≥6 months and <10 years by measurement of P.
- Trial name
- NCT01954264
- Testing
- Capillary blood sample, Data collection
- Where
- 3 sites in Burkina Faso, Senegal
- Volunteers
- 2,421 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Yellow Fever
Trial of an Inactivated Yellow Fever Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 1 mcg and 5 mcg of HydroVax-002 YFV vaccine given intramuscularly on Day 1 and Day 29…
- Trial name
- NCT05172544
- Testing
- HydroVax-002 YFV
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Najit Technologies, Inc.
Malaria
A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh
This is a study assessing safety and efficacy of current national guidelines for the treatment of uncomplicated malaria in Bangladesh as well as to assess the G6PD status among the enrolled patients.
- Trial name
- NCT02389374
- Testing
- chloroquine, Artemether-lumefantrine combination, Primaquine
- Volunteers
- 181 people
- Sponsor
- Menzies School of Health Research
Malaria,Falciparum
Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54
Objectives: Primary: To characterize the infectivity of the new lot of Plasmodium falciparum strain 3D7 within the standard WRAIR CHMI model as compared to the current lot (historical data) Secondary: To assess safety of the new…
- Trial name
- NCT03882528
- Testing
- Plasmodium falciparum malaria parasite
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235033)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 3 sites in Côte d’Ivoire, Gabon and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Mucosal Leishmaniasis, Cutaneous Leishmaniasis
Miltefosine to Treat Mucocutaneous Leishmaniasis
The purpose of this Treatment Investigational New Drug application was to make miltefosine available for mucocutaneous leishmaniasis patients presenting in the United States.
- Trial name
- NCT01050907
- Testing
- Miltefosine
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Knight Therapeutics (USA) Inc
Dengue, Dengue Hemorrhagic Fever
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
The purpose of this study is to generate immunogenicity and safety data in preparation for efficacy studies in Latin America. Primary Objectives: To describe the immune response to dengue viruses before and after each vaccination…
- Trial name
- NCT01187433
- Testing
- Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus, NaCl 0.9%, Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for…
- Trial name
- NCT03423173
- Testing
- TAK-003
- Where
- 14 sites in United States
- Volunteers
- 923 people, healthy volunteers welcome
- Sponsor
- Takeda
Malaria
Safety and Efficacy Study of IV Artesunate to Treat Malaria
The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.
- Trial name
- NCT00298610
- Testing
- Artesunate, Malarone
- Where
- Kenya
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Plasmodium Falciparum Malaria
FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria is a disease that affects many people in Africa and in Mali. It is caused by germs that are spread by mosquito bites. This study will look at the safety, effectiveness, and best dose of an experimental malaria vaccine in…
- Trial name
- NCT00349713
- Testing
- FMP2.1/AS02A, Rabies vaccine (RabAvert)
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
MALARIA, FEVER
Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
The study is a randomized open label clinical trial to verify the reproducibility of a sporozoite challenge model for Plasmodium vivax in humans.
- Conditions
- MALARIA, FEVER, Sweating Fever, Chills
- Trial name
- NCT00367380
- Testing
- 413ABM, 414WRR, 418JAL
- Where
- Colombia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Lyme Borreliosis
Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study conducted in two study phases: a run-in phase and a main study phase.
- Trial name
- NCT03769194
- Testing
- VLA15
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 572 people, healthy volunteers welcome
- Sponsor
- Pfizer
Zika Virus, Zika Virus Infection
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
This was a multicenter, randomized study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo.
- Conditions
- Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections
- Trial name
- DNA (NCT03110770)
- Testing
- VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP
- Where
- 17 sites in United States, Brazil and 7 more
- Volunteers
- 2,428 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Seizure, Epilepsy
Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria
Pediatric cerebral malaria (CM) affects more than 3 million children each year killing ~20% and leaving one third of survivors with long term neurologic and psychiatric sequelae.
- Conditions
- Seizure, Epilepsy, Cerebral Malaria
- Trial name
- LVT1 (NCT01660672)
- Testing
- LEVETIRACETAM
- Where
- Malawi
- Volunteers
- 7 people
- Sponsor
- University of Rochester
Healthy
First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
The primary purpose of this study was to investigate the safety and tolerability of M5717 and to characterize the Pharmacokinetics (PK) /Pharmacodynamic relationship between M5717 PK and parasite clearance in healthy participants…
- Trial name
- NCT03261401
- Testing
- M5717
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Compulsive Buying
Memantine Treatment of Compulsive Buying
This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.
- Trial name
- NCT00830375
- Testing
- Memantine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Minnesota
Lyme Arthritis, Lyme Disease
Symptomatic Management of Lyme Arthritis
Lyme arthritis resolves with appropriate antimicrobial treatment in a majority of patients, but 10-20% of patients develop antibiotic-refractory Lyme arthritis with prolonged arthritis symptoms and treatment courses.
- Conditions
- Lyme Arthritis, Lyme Disease, Arthritis
- Trial name
- NCT04038346
- Testing
- Naproxen, Acetaminophen
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Desiree Neville, MD